Optimal biologic dose of metronomic chemotherapy regimens is associated with maximum antiangiogenic activity

Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer

2004 • 10,779 citations

Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer

2004 • 1,935 citations

Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer.

2000 • 1,536 citations

Clinical translation of angiogenesis inhibitors

2002 • 1,518 citations

The anti-angiogenic basis of metronomic chemotherapy

2004 • 1,363 citations

Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity

2000 • 1,159 citations

A Randomized Trial of Adjuvant Chemotherapy with Uracil–Tegafur for Adenocarcinoma of the Lung

2004 • 792 citations

Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels

2002 • 494 citations

A Multitargeted, Metronomic, and Maximum-Tolerated Dose “Chemo-Switch” Regimen is Antiangiogenic, Producing Objective Responses and Survival Benefit in a Mouse Model of Cancer

2004 • 479 citations

Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells.

2003 • 458 citations

Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs.

2002 • 433 citations

Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis

2005 • 331 citations

Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water.

2002 • 313 citations

Differences in therapeutic indexes of combination metronomic chemotherapy and an anti-VEGFR-2 antibody in multidrug-resistant human breast cancer xenografts.

2002 • 241 citations

Fibroblast cell interactions with human melanoma cells affect tumor cell growth as a function of tumor progression.

1991 • 217 citations

Metronomic therapy with cyclophosphamide and dexamethasone for prostate carcinoma

2003 • 162 citations

A Comparative Analysis of Low-Dose Metronomic Cyclophosphamide Reveals Absent or Low-Grade Toxicity on Tissues Highly Sensitive to the Toxic Effects of Maximum Tolerated Dose Regimens

2004 • 132 citations

Synergistic effect of metronomic dosing of cyclophosphamide combined with specific antitumor immunotherapy in a murine melanoma model.

2003 • 128 citations

Thalidomide in multiple myeloma, myelodysplastic syndromes and histiocytosis. Analysis of clinical results and of surrogate angiogenesis markers

2001 • 99 citations

c-Myc Interacts with Hypoxia to Induce Angiogenesis In vivo by a Vascular Endothelial Growth Factor-Dependent Mechanism

2004 • 97 citations

The splenic microenvironment is a source of proangiogenesis/inflammatory mediators accelerating the expansion of murine erythroleukemic cells

2005 • 37 citations

Friend virus-induced erythroleukemias: a unique and well-defined mouse model for the development of leukemia.

2003 • 26 citations

Hormonal replacement therapy in breast cancer

2002 • 13 citations

Palliation of relapsed aggressive histology NHL with high-dose celecoxib and 'metronomic' low-dose cyclophosphamide

2004 • 6 citations

Palliation of relapsed aggressive histology NHL with high-dose celecoxib and 'metronomic' low-dose cyclophosphamide

2004 • 4 citations